Healthcare, medical products and pharmaceuticals
Aging populations in an industrialised world and unmet healthcare needs in the developing world are key macro drivers for these industries. They must meet these needs while dealing with increasing cost, environmental and social pressures.
Issues
- Brand/reputation/relationship management
- Accessibility/affordability of healthcare
- Environmental footprint of facilities (hospitals, production facilities)
- Product stewardship/extended producer responsibility
- Responsible supply chain
- Management of product recall
- Sales and marketing practices
- Research and development, including protection of intellectual property (generics), match between global health needs and R&D focus (heart medications versus HIV medications), animal testing bio-ethics and genetic engineering
- Workforce health and safety—in particular, for the sales force
- Hazardous substances
Client examples
South African public health institution
We carried out occupational health and safety risk assessments at 16 public health facilities, including hospitals, clinics and industrial laundries, to help the facilities to implement sound occupational health and safety management systems.
Global medical products company
We conducted a global inventory and assessment of our client’s corporate citizenship programmes relative to its employees, products, research and development, and supply-chain management. We made an inventory of its current activities and identi.ed opportunities to showcase, integrate, document and enhance its corporate citizenship performance.
Global pharmaceuticals company
We provided independent assurance for the organisation’s management system and external reporting on its global corporate citizenship programme and activities. Our approach included procedures at the group and country levels, analysis of documents and tests of internal management and reporting structures, as well as the gathering of evidence supporting Health, Safety and Environment (HSE) parameters at selected production sites. An Assurance Report was included in the company’s annual corporate citizenship report and on its website.
US pharmaceuticals company
We assessed the company’s activities, processes, systems and controls for selecting suppliers and business partners in China. We identi.ed control risks, process issues and improvement opportunities, and compared the company’s supply-chain-management activities with those of similar pharmaceutical companies and leading practices.
Global pharmaceuticals company
We conducted an assessment of the company’s key compliance risks and the business impacts of those risks. We helped design key compliance processes and made recommendations on centralising its compliance requirements under one newly created management-compliance officer.
US-based global pharmaceuticals manufacturer
This Fortune 500 client sources key raw materials from Asia and was having problems with product quality and intellectual property protection. We assessed its supply-chain processes in the US and Asia and developed an improved risk-control framework for the four key sourcing activities – strategy development, set-up, execution and termination.
